Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 16/20 | 0.66 |
| ▸ | CCNH | P51946 | 14/20 | 0.66 |
| ▸ | MNAT1 | P51948 | 11/20 | 0.66 |
| ▸ | CCNK | O75909 | 11/20 | 0.51 |
| ▸ | CDK12 | Q9NYV4 | 11/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.51 |
| ▸ | CDK9 | P50750 | 10/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.50 |
| ▸ | CDK2 | P24941 | 10/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21549456 | 0.81 | CLK1 (0.64) | CDK7CCNHMNAT1 | |
| SCHEMBL12627364 | 0.81 | JAK2 (0.65) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL19054611 | 0.80 | CDK7 (0.64) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL21549451 | 0.80 | JAK2 (0.49) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL24839576 | 0.80 | CDK7 (1.00) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL23336396 | 0.79 | CDK7 (0.72) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL21549440 | 0.77 | CDK7 (0.57) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL20416024 | 0.77 | CDK7 (0.64) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL22994824 | 0.74 | NR4A2 (0.53) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL18078656 | 0.74 | CDK7 (0.71) | CDK7CCNHMNAT1CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 31/4885MNAT1 105/4885 |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 32/4885MNAT1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.